· New milestone for NeuroLead, the active agent screening platform · New publications in scientific journals · Start of Phase I/II clinical trial for Batten disease
Lyon, 28 February 2022 -
GenSight Biologics Announces the Publication in Communications Biology of the Proof-of-Concept for GS030-Drug Product in Non-Human Primates
The
ex vivo retinal stimulation assays also showed that the electrophysiologic response of RGCs expressing ChrimsonR precisely followed the duration and frequency of the light pulses used to activate the opsin. Moreover, localized stimulation of RGCs induced a response coherent with the size and position of the light pulses.
Optogenetic stimulation of RGCs expressing ChrimsonR-tdT can support restoration of visual acuity
The electrophysiological activity of RGCs expressing ChrimsonR-tdT was consistent with the direction and speed of a moving stimulus. Furthermore, the spatiotemporal activation of treated retinas was specific to the shape of the moving symbols presented (square, circle, cross of different sizes), indicating the ability to discriminate between patterns. This level of pattern discrimination corresponded to a Snellen visual acu